Cargando…
36P Alterations in tumour-promoting cytokines in cancer patients after SARS-CoV-2 infection
Autores principales: | De Winter, F.H., Hotterbeekx, A., Huizing, M., Konnova, A., Jongers, B. 's, Jairam, R.K., Moons, P., Roelant, E., Le Blon, D., Vanden Berghe, W., Janssens, A., Lybaert, W., Croes, L., Vulsteke, C., Malhotra-Kumar, S., Goossens, H., Berneman, Z., Peeters, M., Van Dam, P., Kumar-Singh, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662598/ http://dx.doi.org/10.1016/j.annonc.2021.10.052 |
Ejemplares similares
-
Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients
por: De Winter, Fien H. R., et al.
Publicado: (2021) -
Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests
por: van Dam, Peter, et al.
Publicado: (2021) -
SARS-CoV-2 and cancer: Are they really partners in crime?
por: van Dam, Peter A., et al.
Publicado: (2020) -
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
por: Konnova, Angelina, et al.
Publicado: (2022) -
1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
por: Debie, Y., et al.
Publicado: (2022)